Initial 12-month efficacy results from a Phase IIA trial demonstrate positive effects on pain and osteoporosis blood markers from a single administration of Bone Therapeutics’ PREOB® in the 1st cohort of 7 patients.
The trial is designed to evaluate one intravenous administration of PREOB in patients who no longer respond to anti-osteoporotic therapy. Twenty patients will be enrolled and followed up for 12 months.
In this first cohort, patients experienced a pronounced and clinically relevant decrease in pain of more than 40%, reaching a maximum at six months post-treatment.
The results suggest that one dose of PREOB may progressively stimulate bone remodelling, with a bone formation-to-resorption ratio more favorable than that generally reported with other anti-osteoporotic agents in the same patient population.
Previous results released in mid-2015 from the PREOB Phase IIA trial indicated migration of intravenously-injected cells to the bones, with no treatment-related safety concerns in the 1st patient cohort.
Initial 12-month efficacy results from a Phase IIA trial demonstrate positive effects on pain and osteoporosis blood markers from a single administration of Bone Therapeutics' PREOB® in the 1st cohort of 7 patients.
The trial is designed to evaluate one intravenous administration of PREOB in patients who no longer respond to anti-osteoporotic...
Initial 12-month efficacy results from a Phase IIA trial demonstrate positive effects on pain and osteoporosis blood markers from a single administration of Bone Therapeutics’ PREOB® in the 1st cohort of 7 patients.
The trial is designed to evaluate one intravenous administration of PREOB in patients who no longer respond to anti-osteoporotic therapy. Twenty patients will be enrolled and followed up for 12 months.
In this first cohort, patients experienced a pronounced and clinically relevant decrease in pain of more than 40%, reaching a maximum at six months post-treatment.
The results suggest that one dose of PREOB may progressively stimulate bone remodelling, with a bone formation-to-resorption ratio more favorable than that generally reported with other anti-osteoporotic agents in the same patient population.
Previous results released in mid-2015 from the PREOB Phase IIA trial indicated migration of intravenously-injected cells to the bones, with no treatment-related safety concerns in the 1st patient cohort.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
